Tuesday, August 23, 2022

Baudax Bio (BXRX)
Notice of Patent Allowance For Claims Covering ANJESO

Baudax Bio is a pharmaceutical company focused on innovative products for acute care settings. ANJESO is the first and only 24-hour, intravenous (IV) COX-2 preferential non-steroidal anti-inflammatory (NSAID) for the management of moderate to severe pain. In addition to ANJESO, Baudax Bio has a pipeline of other innovative pharmaceutical assets including two novel neuromuscular blocking agents (NMBs) and a proprietary chemical reversal agent specific to these NMBs. For more information, please visit www.baudaxbio.com.

Gregory Aurand, Senior Research Analyst, Healthcare Services & Medical Devices, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Notice of Allowance for patent application.  Yesterday, Baudax Bio announced the US Patent and Trademark Office (USPTO) provided a Notice of Allowance for patent application No. 16/297095 (the ‘095 application).  The USPTO typically issues a Notice after determining the patent application should be granted.

The Patent should be granted in the next few months.  The patent application covers the multiple doses of ANJESO for the treatment of moderate to severe pain, and a reduction in use of rescue analgesics 48 hours following the first dose.  The patent from the ‘095 titled application “Methods of administering intravenous meloxicam in a bolus dose”, once issued, will be eligible for listing in the FDA’s Orange Book. …

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.